TOP TEN perturbations for NM_000232 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000232
Selected probe(set): 226112_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000232 (226112_at) across 5339 perturbations tested by GENEVESTIGATOR:

OPM-1 / MM1.S

Relative Expression (log2-ratio):-3.683402
Number of Samples:4 / 4
Experimental OPM-1
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code:
Control MM1.S
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code:

succinate dehydrogenase B depletion study 1 (siRNA) / control siRNA transfected Hep3B cell sample

Relative Expression (log2-ratio):3.5365324
Number of Samples:3 / 3
Experimental succinate dehydrogenase B depletion study 1 (siRNA)
Hep3B cells stably transfected with short hairpin vectors containing an siRNA directed to the subunit B of the succinate dehydrogenase.
Control control siRNA transfected Hep3B cell sample
Hep3B cells stably transfected with empty siRNA expression vector (pU6).

LPS study 4 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):3.4157534
Number of Samples:2 / 2
Experimental LPS study 4
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

precursor-B-ALL study 3 (hyperdiploid) / precursor-B-ALL study 3 (BCR-ABL)

Relative Expression (log2-ratio):3.294755
Number of Samples:17 / 4
Experimental precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (BCR-ABL)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (PAX5-rearranged) / precursor-B-ALL study 3 (hyperdiploid)

Relative Expression (log2-ratio):-3.2554483
Number of Samples:6 / 17
Experimental precursor-B-ALL study 3 (PAX5-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (hyperdiploid) / precursor-B-ALL study 3 (unspecified)

Relative Expression (log2-ratio):3.1450481
Number of Samples:17 / 22
Experimental precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (unspecified)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (no specific subtype). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (hyperdiploid) / precursor-B-ALL study 3 (TEL-AML1)

Relative Expression (log2-ratio):3.0939064
Number of Samples:17 / 15
Experimental precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):3.0607672
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

HCC study 9 (HBV; HCV) / normal liver tissue

Relative Expression (log2-ratio):-3.0522919
Number of Samples:2 / 10
Experimental HCC study 9 (HBV; HCV)
Liver tissue biopsy sample from patients with Hepatitis B and C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)

Relative Expression (log2-ratio):2.7157316
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA cycT1)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control cycT1 depletion study 2 (shRNA)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.